Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

NCT00927914 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Diabetic Sensorimotor Polyneuropathy

Interventions

DRUG: Ranirestat
DRUG: Placebo

Sponsor

Eisai Inc.